Withaferin A

Research use only, not for human use.

Withaferin A is a steroid lactone that displays anti-inflammatory, antitumor and antiangiogenic activity, potently inhibits NF-κB activation.

Withaferin A is a steroid lactone that displays anti-inflammatory, antitumor and antiangiogenic activity, potently inhibits NF-κB activation by preventing the TNF-induced activation of IKKβ via a thioalkylation-sensitive redox mechanism; potently inhibits the chymotrypsin-like activity of a purified rabbit 20S proteasome (IC50=4.5 uM) and 26S proteasome in human prostate cancer cultures (at 5-10 uM) and xenografts (4-8 mg/kg/day), inhibits cell proliferation in HUVECs (IC50 =12 nM).(In Vitro):Withaferin A has antiinflammatory activity, and potently inhibits NF-kB activation by preventing the TNF-induced activation of Ik-B kinase beta via a thioalkylation-sensitive redox mechanism. Withaferin A also has anticancer activity. Withaferin A targets the IF protein vimentin, causes aggregation of vimentin filaments in bovine aortic endothelial cells (BAECs) at 3 μM, and induces vimentin fragmentation in endothelial cells at 10 μM. Withaferin A (0.5, 1.5 μM) alone or incombination with cisplatin (CIS) dose-dependently reduces tumorigenic potential of ALDH1 positive cancer stem cells (CSCs).(In Vivo):Withaferin A (2 mg/kg, i.p.) shows potent angiogenesis inhibitory activity via vimentin in mice. Withaferin A (2 mg/kg) combined with cisplatin (CIS) regulates the expression of ALDH1 marker, and downregulates the expression of securin in tumors collected from mice.

Withaferin A has antiinflammatory activity, and potently inhibits NF-kB activation by preventing the TNF-induced activation of Ik-B kinase beta via a thioalkylation-sensitive redox mechanism. Withaferin A also has anticancer activity. Withaferin A targets the IF protein vimentin, causes aggregation of vimentin filaments in bovine aortic endothelial cells (BAECs) at 3 μM, and induces vimentin fragmentation in endothelial cells at 10 μM. Withaferin A (0.5, 1.5 μM) alone or incombination with cisplatin (CIS) dose-dependently reduces tumorigenic potential of ALDH1 positive cancer stem cells (CSCs).

Withaferin A (2 mg/kg, i.p.) shows potent angiogenesis inhibitory activity via vimentin in mice. Withaferin A (2 mg/kg) combined with cisplatin (CIS) regulates the expression of ALDH1 marker, and downregulates the expression of securin in tumors collected from mice.

NSC 101088 | NSC 273757

Apoptosis

NF-κB

NF-κB

Inflammation/Immunology

——

5119-48-2

470.6

C28H38O6

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (106.25 mM)

CC12C(CCC2[C@@H](C)[C@H](O)CC(CO3)=C(C)C3=O)C4C[C@@H]5[C@](C6(C)C4CC1)(O5)[C@@H](O)C=CC6=O

(4β,5β,6β,22R)-5,6-Epoxy-4,22,27-trihydroxy-1-oxoergosta-2,24-dien-26-oic acid δ-lactone

(-20℃)

With Ice Pack

≥ 2 years